TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).

Mariano Provencio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.